HALB (Halberd) Stock Based Compensation: $0.00 Mil (TTM As of Jul. 2023)


What is Halberd Stock Based Compensation?

Halberd HALB Stock Based Compensation is $0.00 Mil as of Jul. 2023.

Halberd's Stock Based Compensation for the six months ended in Jul. 2023 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

Halberd Stock Based Compensation Related Terms

Halberd Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Halberd's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Stock Based Compensation Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Stock Based Compensation
0.00 0.00 0.00

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Stock Based Compensation 0.00 0.00 0.00

Halberd Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
Halberd (HALB) has a Stock Based Compensation of $0.00 Mil as of Jul. 2023. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Halberd and its competitors.
Is Halberd's Stock Based Compensation too high?
Halberd's current Stock Based Compensation is $0.00 Mil.
How does Halberd's Stock Based Compensation compare to GRI and OCEA?
Halberd's Stock Based Compensation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Halberd and its competitors. Halberd's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Stock Based Compensation of $0.00 Mil. The current Stock Based Compensation is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Halberd (HALB), the current Stock Based Compensation is $0.00 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.